# Froedtert Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/froedtert-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 69.3 |
| Citations | 149,708 |
| City | Milwaukee |
| Country | US |
| Description | Froedtert Hospital is a research organisation in Milwaukee, US. OpenAlex records 3,039 works and 149,708 citations for it. 938 researchers list it as their most recent affiliation. |
| Homepage | https://www.froedtert.com/ |
| OpenAlex ID | https://openalex.org/I1310546135 |
| Region | Wisconsin |
| Researchers | 938 |
| ROR ID | https://ror.org/01nhrc260 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q5505153 |
| Works | 3,039 |

## University papers

Showing 12 of 34.

- [Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers](https://scholariq.org/papers/tumor-mutational-burden-as-an-independent-predictor-of-response-to-immunotherapy/)
- [PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy](https://scholariq.org/papers/pd-l1-expression-as-a-predictive-biomarker-in-cancer-immunotherapy/)
- [International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease](https://scholariq.org/papers/international-evidence-based-consensus-diagnostic-criteria-for-hhv-8-negative/)
- [Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial](https://scholariq.org/papers/genomic-and-transcriptomic-profiling-expands-precision-cancer-medicine-the/)
- [Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial](https://scholariq.org/papers/safety-pharmacokinetic-pharmacodynamic-and-efficacy-data-for-the-oral-mek/)
- [Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial](https://scholariq.org/papers/activity-of-the-oral-mek-inhibitor-trametinib-in-patients-with-advanced-melanoma/)
- [Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative](https://scholariq.org/papers/personalized-medicine-in-a-phase-i-clinical-trials-program-the-md-anderson/)
- [International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease](https://scholariq.org/papers/international-evidence-based-consensus-treatment-guidelines-for-idiopathic/)
- [Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics](https://scholariq.org/papers/analysis-of-i-ntrk-i-alterations-in-pan-cancer-adult-and-pediatric-malignancies/)
- [PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists](https://scholariq.org/papers/prep-awareness-familiarity-comfort-and-prescribing-experience-among-us-primary/)
- [Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors](https://scholariq.org/papers/phase-i-study-of-ro4929097-a-gamma-secretase-inhibitor-of-notch-signaling-in/)
- [Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review](https://scholariq.org/papers/health-care-provider-barriers-to-hiv-pre-exposure-prophylaxis-in-the-united/)

## University researchers

- [Marc DeMoya](https://scholariq.org/researchers/marc-demoya/)
- [Andrew E. Petroll](https://scholariq.org/researchers/andrew-e-petroll/)

## University top topics

Showing 8 of 25.

- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Palliative Care and End-of-Life Issues](https://scholariq.org/topics/palliative-care-and-end-of-life-issues/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Acute Ischemic Stroke Management](https://scholariq.org/topics/acute-ischemic-stroke-management/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Pharmaceutical Practices and Patient Outcomes](https://scholariq.org/topics/pharmaceutical-practices-and-patient-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.